Galmed Pharmaceuticals Ltd.
GLMD
$1.39
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.41% | -59.18% | 29.76% | 29.76% | 30.33% |
| Total Depreciation and Amortization | -- | -100.00% | 722.22% | 722.22% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.35% | 1,435.29% | 700.00% | 700.00% | -5.52% |
| Change in Net Operating Assets | 80.36% | -159.11% | -145.54% | -145.54% | -1,894.44% |
| Cash from Operations | 36.23% | -119.27% | 25.60% | 25.60% | -7.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -153.47% | -255.73% | 97.45% | 97.45% | -68.02% |
| Cash from Investing | -153.47% | -255.73% | 97.45% | 97.45% | -68.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.30% | -467.13% | 156.65% | 156.65% | -306.40% |